Jornay Pm is a drug owned by Ironshore Pharmaceuticals Inc A Wholly Owned Sub Of Collegium Pharmaceutical Inc. It is protected by 16 US drug patents filed from 2018 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 23, 2032. Details of Jornay Pm's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9028868 | Methods and compositions for treatment of attention deficit disorder |
Mar, 2032
(7 years from now) | Active |
| US9034902 | Methods for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | Active |
| US8916588 | Methods for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | Active |
| US9603809 | Methods of treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | Active |
| US10292937 | Methods of treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | Active |
| US10617651 | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | Active |
| US10881618 | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | Active |
| US11911518 | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | Active |
| US11241391 | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | Active |
| US11241392 | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | Active |
| US10182995 | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | Active |
| US8927010 | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | Active |
| US9023389 | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | Active |
| US10905652 | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | Active |
| US9498447 | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | Active |
| US9283214 | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(7 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Jornay Pm's patents.
Latest Legal Activities on Jornay Pm's Patents
Given below is the list of recent legal activities going on the following patents of Jornay Pm.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 17 Jul, 2024 | US10905652 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 19 Jun, 2024 | US10881618 |
| Email Notification Critical | 08 May, 2024 | US11911518 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 08 May, 2024 | US9498447 |
| Patent eCofC Notification | 07 May, 2024 | US11911518 |
| Recordation of Patent eCertificate of Correction | 07 May, 2024 | US11911518 |
| Mail Patent eCofC Notification | 07 May, 2024 | US11911518 |
| Email Notification Critical | 07 May, 2024 | US11911518 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 20 Mar, 2024 | US10881618 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 20 Mar, 2024 | US11241392 |
FDA has granted several exclusivities to Jornay Pm. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Jornay Pm, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Jornay Pm.
Exclusivity Information
Jornay Pm holds 1 exclusivities. All of its exclusivities have expired in 2021. Details of Jornay Pm's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 08, 2021 |
US patents provide insights into the exclusivity only within the United States, but Jornay Pm is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Jornay Pm's family patents as well as insights into ongoing legal events on those patents.
Jornay Pm's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Jornay Pm's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 23, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Jornay Pm Generic API suppliers:
Methylphenidate Hydrochloride is the generic name for the brand Jornay Pm. 42 different companies have already filed for the generic of Jornay Pm, with Specgx Llc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Jornay Pm's generic
Alternative Brands for Jornay Pm
Jornay Pm which is used for treating Attention Deficit Hyperactivity Disorder (ADHD)., has several other brand drugs in the same treatment category and using the same active ingredient (Methylphenidate Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Purdue Pharma Lp |
| |||
| Rhodes Pharms |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Methylphenidate Hydrochloride. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Aytu Biopharma |
| |||
| Commave Therap |
| |||
| Janssen Pharms |
| |||
| Nextwave |
| |||
| Nextwave Pharms |
| |||
| Sandoz |
| |||
| Specgx Llc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Methylphenidate Hydrochloride, Jornay Pm's active ingredient. Check the complete list of approved generic manufacturers for Jornay Pm
About Jornay Pm
Jornay Pm is a drug owned by Ironshore Pharmaceuticals Inc A Wholly Owned Sub Of Collegium Pharmaceutical Inc. It is used for treating Attention Deficit Hyperactivity Disorder (ADHD). Jornay Pm uses Methylphenidate Hydrochloride as an active ingredient. Jornay Pm was launched by Ironshore Pharms in 2018.
Approval Date:
Jornay Pm was approved by FDA for market use on 08 August, 2018.
Active Ingredient:
Jornay Pm uses Methylphenidate Hydrochloride as the active ingredient. Check out other Drugs and Companies using Methylphenidate Hydrochloride ingredient
Treatment:
Jornay Pm is used for treating Attention Deficit Hyperactivity Disorder (ADHD).
Dosage:
Jornay Pm is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 40MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 80MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 100MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 20MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 60MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |